World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
74
Citations
19352
World Ranking
19416
National Ranking
9672

Jane L. Liesveld publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jane L. Liesveld sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 385 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jane L. Liesveld D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jane L. Liesveld sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 74 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jane L. Liesveld is affiliated with the University of Rochester Medical Center in the United States. Their research primarily falls within the broad field of Medicine, with a significant focus on Hematology. Additional subfields of study in their work include Public Health, Environmental and Occupational Health, Molecular Biology, Oncology, and Genetics.

Their scholarly contributions emphasize topics related to hematologic malignancies and stem cell research. Key thematic areas of study in their work include:

  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Palliative Care and End-of-Life Issues
  • Childhood Cancer Survivors' Quality of Life
  • Acute Lymphoblastic Leukemia research
  • Cancer survivorship and care
  • Chronic Myeloid Leukemia Treatments

Liesveld has published extensively in a range of professional journals. Their frequent publication venues include:

  • Blood
  • Journal of Geriatric Oncology
  • Blood Advances
  • Transplantation and Cellular Therapy
  • UNC Libraries

Selected recent papers authored or co-authored by Liesveld include:

  • Stem cell homing: From physiology to therapeutics, 2020, Stem Cells
  • Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study, 2021, Blood
  • Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML, 2021, Leukemia
  • Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem, 2022, Cancers
  • Survival following allogeneic transplant in patients with myelofibrosis, 2020, Blood Advances

Their research collaborations include repeated partnerships with several frequent co-authors, such as:

  • Eric Huselton
  • Jason H. Mendler
  • Kah Poh Loh
  • Michael W. Becker
  • Andrea Baran

Best Publications

  • BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

    Eleni D. Lagadinou;Alexander Sach;Kevin Callahan;Randall M. Rossi

  • A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

    Corey S. Cutler;Stephanie J. Lee;Peter Greenberg;H. Joachim Deeg

  • The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

    Neal Flomenberg;Steven M. Devine;John F. DiPersio;Jane L. Liesveld

  • Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

    Steven M. Devine;Neal Flomenberg;David H. Vesole;Jane Liesveld

  • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

    Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End

  • Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy

    Peter Mauch;Louis Constine;Joel Greenberger;William Knospe

  • Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.

    Jessica L. Halliley;Jessica L. Halliley;Christopher M. Tipton;Jane Liesveld;Alexander F. Rosenberg

  • An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

    Monica L. Guzman;Randall M. Rossi;Sundar Neelakantan;Xiaojie Li

  • A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

    Jacob M. Rowe;Donna Neuberg;William Friedenberg;John M. Bennett

  • Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

    S. Mustjoki;M. Ekblom;T. P. Arstila;I. Dybedal

  • Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways.

    Martin S. Zand;Thuong Vo;Jennifer Huggins;Raymond Felgar

  • A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

    Jeffrey E. Lancet;Ivana Gojo;Jason Gotlib;Eric J. Feldman

  • The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

    Jonathan W. Friedberg;Julie M. Vose;Jennifer L. Kelly;Faith Young

  • Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    Javier Bolaños-Meade;Ran Reshef;Raphael Fraser;Mingwei Fei

  • Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data

    Duane C. Hassane;Monica L. Guzman;Cheryl Corbett;Xiaojie Li

  • Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.

    Tzu-Chieh Ho;Mark LaMere;Brett M. Stevens;John M. Ashton

  • Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells

    Shanshan Pei;Mohammad Minhajuddin;Kevin P. Callahan;Marlene Balys

  • Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants.

    Aaron P. Rapoport;Luc F. Miller Watelet;Tammy Linder;Shirley Eberly

  • Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells.

    Jane L. Liesveld;Jill M. Winslow;Karen E. Frediani;Daniel H. Ryan

  • Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

    Satu Mustjoki;Marja Ekblom;T. Petteri Arstila;Ingunn Dybedal

Frequent Co-Authors

Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Louis S. Constine
Louis S. Constine University of Rochester Medical Center
Bipin N. Savani
Bipin N. Savani Vanderbilt University Medical Center
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
Craig T. Jordan
Craig T. Jordan University of Colorado Anschutz Medical Campus
John F. DiPersio
John F. DiPersio Washington University in St. Louis
Brent R. Logan
Brent R. Logan Medical College of Wisconsin
Michael R. King
Michael R. King Vanderbilt University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As demand grows for qualified healthcare professionals, online programs have made it more accessible to advance your career or change paths within the medical field. Those interested in specialized care should consider reviewing the cheapest online fnp programs, offering a pathway to becoming a Family Nurse Practitioner.

For those just starting out or seeking to earn their initial credential, there are flexible nursing school online options designed to fit your schedule and budget. Registered Nurses aiming to advance their credentials can find accelerated and affordable rn to bsn cheapest programs, which can open up further career opportunities and higher pay.

For those seeking leadership, teaching, or research positions, exploring programs through the cheapest dnp programs is ideal. Whether you're starting or advancing your studies, these online degrees pave new pathways toward rewarding roles in health care.

Best Scientists Citing Jane L. Liesveld

Trending Scientists

Recently Published Articles